Cargando…

Self-antigen–specific CD8(+) T cell precursor frequency determines the quality of the antitumor immune response

A primary goal of cancer immunotherapy is to improve the naturally occurring, but weak, immune response to tumors. Ineffective responses to cancer vaccines may be caused, in part, by low numbers of self-reactive lymphocytes surviving negative selection. Here, we estimated the frequency of CD8(+) T c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzuto, Gabrielle A., Merghoub, Taha, Hirschhorn-Cymerman, Daniel, Liu, Cailian, Lesokhin, Alexander M., Sahawneh, Diana, Zhong, Hong, Panageas, Katherine S., Perales, Miguel-Angel, Altan-Bonnet, Grégoire, Wolchok, Jedd D., Houghton, Alan N.
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715122/ https://www.ncbi.nlm.nih.gov/pubmed/19332877 http://dx.doi.org/10.1084/jem.20081382

Ejemplares similares

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2009)

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2012)

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
por: Hirschhorn, Daniel, et al.
Publicado: (2021)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
por: Cohen, Adam D., et al.
Publicado: (2010)

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
por: Avogadri, Francesca, et al.
Publicado: (2010)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope
por: Schaer, David A., et al.
Publicado: (2011)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks
por: Tkach, Karen E, et al.
Publicado: (2014)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
por: Gupta, Aditi, et al.
Publicado: (2021)

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
por: Budhu, Sadna, et al.
Publicado: (2021)

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Yang, Ning, et al.
Publicado: (2022)

Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent
por: Diab, Adi, et al.
Publicado: (2013)

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
por: Maus, Marcela V, et al.
Publicado: (2017)

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
por: Momtaz, Parisa, et al.
Publicado: (2017)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
por: Zamarin, Dmitriy, et al.
Publicado: (2017)

OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs
por: Yang, Ning, et al.
Publicado: (2023)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
por: Yuan, Jianda, et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
por: He, Changhao, et al.
Publicado: (2022)

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
por: Choi, Hyejin, et al.
Publicado: (2019)

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
por: Perales, Miguel-Angel, et al.
Publicado: (2008)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vpmndehmh7la0em5enrek10k57